Your browser doesn't support javascript.
loading
Clinical Characteristics and Transplant-Free Survival Across the Spectrum of Pulmonary Vascular Disease.
Hemnes, Anna R; Leopold, Jane A; Radeva, Milena K; Beck, Gerald J; Abidov, Aiden; Aldred, Micheala A; Barnard, John; Rosenzweig, Erika B; Borlaug, Barry A; Chung, Wendy K; Comhair, Suzy A A; Desai, Ankit A; Dubrock, Hilary M; Erzurum, Serpil C; Finet, J Emanuel; Frantz, Robert P; Garcia, Joe G N; Geraci, Mark W; Gray, Michael P; Grunig, Gabriele; Hassoun, Paul M; Highland, Kristin B; Hill, Nicholas S; Hu, Bo; Kwon, Deborah H; Jacob, Miriam S; Jellis, Christine L; Larive, A Brett; Lempel, Jason K; Maron, Bradley A; Mathai, Stephen C; McCarthy, Kevin; Mehra, Reena; Nawabit, Rawan; Newman, John H; Olman, Mitchell A; Park, Margaret M; Ramos, Jose A; Renapurkar, Rahul D; Rischard, Franz P; Sherer, Susan G; Tang, W H Wilson; Thomas, James D; Vanderpool, Rebecca R; Waxman, Aaron B; Wilcox, Jennifer D; Yuan, Jason X-J; Horn, Evelyn M.
Afiliação
  • Hemnes AR; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: anna.r.hemnes@vumc.org.
  • Leopold JA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Radeva MK; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Beck GJ; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Abidov A; Division of Cardiology, Wayne State University, Detroit, Michigan, USA.
  • Aldred MA; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Barnard J; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Rosenzweig EB; Department of Pediatrics and Medicine, Columbia University, New York, New York, USA.
  • Borlaug BA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Chung WK; Department of Pediatrics, Columbia University, New York, New York, USA.
  • Comhair SAA; Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
  • Desai AA; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Dubrock HM; Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Erzurum SC; Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Finet JE; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Frantz RP; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Garcia JGN; Department of Medicine, University of Arizona, Tucson, Arizona, USA.
  • Geraci MW; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Gray MP; Department of Cardiology, The University of Sydney, Sydney, New South Wales, Australia.
  • Grunig G; Department of Environmental Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Hassoun PM; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Highland KB; Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Hill NS; Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
  • Hu B; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Kwon DH; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Jacob MS; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Jellis CL; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Larive AB; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Lempel JK; Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Maron BA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Mathai SC; Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • McCarthy K; Respiratory Solutions, ERT, Inc, Cleveland, Ohio, USA.
  • Mehra R; Neurologic and Respiratory Institutes, Cleveland Clinic, Cleveland, Ohio, USA.
  • Nawabit R; Pediatrics Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Newman JH; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Olman MA; Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
  • Park MM; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Ramos JA; Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Renapurkar RD; Imaging Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Rischard FP; Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Arizona, Tucson, Arizona, USA.
  • Sherer SG; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
  • Tang WHW; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
  • Thomas JD; Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, Illinois, USA.
  • Vanderpool RR; Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
  • Waxman AB; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Wilcox JD; Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Cleveland, Ohio, USA.
  • Yuan JX; Department of Medicine, University of California, San Diego, California, USA.
  • Horn EM; Perkin Heart Failure Center, Division of Cardiology, Weill Cornell Medicine, New York, New York, USA.
J Am Coll Cardiol ; 80(7): 697-718, 2022 08 16.
Article em En | MEDLINE | ID: mdl-35953136
ABSTRACT

BACKGROUND:

PVDOMICS (Pulmonary Vascular Disease Phenomics) is a precision medicine initiative to characterize pulmonary vascular disease (PVD) using deep phenotyping. PVDOMICS tests the hypothesis that integration of clinical metrics with omic measures will enhance understanding of PVD and facilitate an updated PVD classification.

OBJECTIVES:

The purpose of this study was to describe clinical characteristics and transplant-free survival in the PVDOMICS cohort.

METHODS:

Subjects with World Symposium Pulmonary Hypertension (WSPH) group 1-5 PH, disease comparators with similar underlying diseases and mild or no PH and healthy control subjects enrolled in a cross-sectional study. PH groups, comparators were compared using standard statistical tests including log-rank tests for comparing time to transplant or death.

RESULTS:

A total of 1,193 subjects were included. Multiple WSPH groups were identified in 38.9% of PH subjects. Nocturnal desaturation was more frequently observed in groups 1, 3, and 4 PH vs comparators. A total of 50.2% of group 1 PH subjects had ground glass opacities on chest computed tomography. Diffusing capacity for carbon monoxide was significantly lower in groups 1-3 PH than their respective comparators. Right atrial volume index was higher in WSPH groups 1-4 than comparators. A total of 110 participants had a mean pulmonary artery pressure of 21-24 mm Hg. Transplant-free survival was poorest in group 3 PH.

CONCLUSIONS:

PVDOMICS enrolled subjects across the spectrum of PVD, including mild and mixed etiology PH. Novel findings include low diffusing capacity for carbon monoxide and enlarged right atrial volume index as shared features of groups 1-3 and 1-4 PH, respectively; unexpected, frequent presence of ground glass opacities on computed tomography; and sleep alterations in group 1 PH, and poorest survival in group 3 PH. PVDOMICS will facilitate a new understanding of PVD and refine the current PVD classification. (Pulmonary Vascular Disease Phenomics Program PVDOMICS [PVDOMICS]; NCT02980887).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Doenças Vasculares / Hipertensão Pulmonar Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Doenças Vasculares / Hipertensão Pulmonar Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2022 Tipo de documento: Article